Zoetis Cuts Guidance As Librela Safety Questions Test Growth Story [Yahoo! Finance]
Zoetis Inc. Class A (ZTS)
Last zoetis inc. class a earnings: 2/13 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.zoetis.com
Company Research
Source: Yahoo! Finance
Zoetis (NYSE:ZTS) reduced its full year guidance after raising safety concerns around its osteoarthritis drug Librela. Management said it intends to address questions on Librela with science based evidence on safety and efficacy. The update has drawn attention because Librela is an important product within Zoetis's animal health portfolio. For investors watching Zoetis at a share price of $118.15, the guidance cut tied to Librela comes on top of a weak longer term share performance. The stock is down 3.4% over the past week and 6.7% over the past month, with a 1 year return of a 27.4% decline and a 3 year return of a 26.3% decline. Over 5 years, Zoetis has recorded a 20.4% decline, which frames how sensitive sentiment can be to product specific headlines. Because Librela plays a key role in the NYSE:ZTS product suite, the way Zoetis responds to safety questions will likely be closely watched. Management's plan to lean on scientific data may influence how vets, pet owners and
Show less
Read more
Impact Snapshot
Event Time:
ZTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZTS alerts
High impacting Zoetis Inc. Class A news events
Weekly update
A roundup of the hottest topics
ZTS
News
- Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Zoetis (NYSE:ZTS) [Yahoo! Finance]Yahoo! Finance
- What Makes Zoetis (ZTS) an Investment Bet? [Yahoo! Finance]Yahoo! Finance
- ?????????????????? (2026?~2036?) [CNET News]CNET News
- Is Zoetis Inc. (ZTS) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- Zoetis (ZTS) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "hold (c-)".MarketBeat
ZTS
Earnings
- 2/12/26 - Beat
ZTS
Sec Filings
- 3/20/26 - Form 4
- 3/10/26 - Form 4
- 2/23/26 - Form 4
- ZTS's page on the SEC website